Compare CYBN & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYBN | TCPC |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.1M | 449.7M |
| IPO Year | N/A | 2012 |
| Metric | CYBN | TCPC |
|---|---|---|
| Price | $8.28 | $5.58 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 2 |
| Target Price | ★ $74.50 | $6.50 |
| AVG Volume (30 Days) | 916.5K | ★ 1.0M |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | ★ 21.98% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $219,119,058.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.81 | $5.29 |
| 52 Week High | $10.73 | $9.48 |
| Indicator | CYBN | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 68.97 | 44.70 |
| Support Level | $7.85 | $5.29 |
| Resistance Level | $9.12 | $5.76 |
| Average True Range (ATR) | 0.51 | 0.15 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 68.59 | 33.73 |
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.